[go: up one dir, main page]

WO2002017898A3 - Compositions et procedes visant a induire une vasorelaxation - Google Patents

Compositions et procedes visant a induire une vasorelaxation Download PDF

Info

Publication number
WO2002017898A3
WO2002017898A3 PCT/US2001/026983 US0126983W WO0217898A3 WO 2002017898 A3 WO2002017898 A3 WO 2002017898A3 US 0126983 W US0126983 W US 0126983W WO 0217898 A3 WO0217898 A3 WO 0217898A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nitric oxide
antioxidant
patient
vasorelaxation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/026983
Other languages
English (en)
Other versions
WO2002017898A2 (fr
Inventor
Meir S Sacks
Dyke Knox Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU8852301A priority Critical patent/AU8852301A/xx
Publication of WO2002017898A2 publication Critical patent/WO2002017898A2/fr
Publication of WO2002017898A3 publication Critical patent/WO2002017898A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition renfermant un ou plusieurs donneurs de monoxyde d'azote et un antioxydant. Le donneur de monoxyde d'azote décrit dans cette invention constitue un substrat utile pour la génération de monoxyde d'azote ; couplées à l'antioxydant, les compositions de l'invention servent à augmenter les taux de monoxyde d'azote chez un patient tout en limitant la production de pernitrites. Il en résulte une vasorelaxation ou vasodilatation n'entraînant pas de lésions tissulaires et cellulaires associées à d'autres procédés de génération de NO. L'invention concerne aussi des traitements de maladies ayant pour symptôme ou impliquant une vasoconstriction. Ces traitements comprennent l'étape consistant à administrer au patient à traiter un donneur de NO, de façon simultanée ou consécutive à un antioxydant, selon une quantité efficace pour induire le degré voulu de vasorelaxation.
PCT/US2001/026983 2000-09-01 2001-08-29 Compositions et procedes visant a induire une vasorelaxation Ceased WO2002017898A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU8852301A AU8852301A (en) 2000-09-01 2001-08-29 Compositions and methods for inducing vasorelaxation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65388700A 2000-09-01 2000-09-01
US09/653,887 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002017898A2 WO2002017898A2 (fr) 2002-03-07
WO2002017898A3 true WO2002017898A3 (fr) 2002-07-04

Family

ID=24622672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026983 Ceased WO2002017898A2 (fr) 2000-09-01 2001-08-29 Compositions et procedes visant a induire une vasorelaxation

Country Status (2)

Country Link
AU (1) AU8852301A (fr)
WO (1) WO2002017898A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566714B2 (en) 2003-11-17 2009-07-28 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206521A (ja) * 2005-01-28 2006-08-10 Univ Of Tokyo 一酸化窒素供与体としてのｎ−ニトロソアミン化合物
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US7862598B2 (en) 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
WO2008080194A1 (fr) * 2006-12-29 2008-07-10 The University Of Queensland Compositions analgésiques et leurs utilisations
US8822509B2 (en) 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US7846400B2 (en) 2007-10-30 2010-12-07 The Invention Science Fund I, Llc Substrates for nitric oxide releasing devices
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
WO2011011092A1 (fr) * 2009-07-22 2011-01-27 University Of Massachusetts Procédés et compositions pour réduire le stress oxydatif
WO2023283332A1 (fr) * 2021-07-07 2023-01-12 Emory University Utilisations d'inhibiteurs d'arginase pour la gestion d'une maladie rénale et de troubles cardiovasculaires

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016983A1 (fr) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Amelioration de la fonction vasculaire par modulation de la production ou de l'activite de l'oxyde nitrique endogene
WO1999038507A1 (fr) * 1998-01-30 1999-08-05 David George Le Couteur Inversion et prevention des aspects du vieillissement importants du point de vue clinique via l'administration par voie orale d'un vasodilatateur de l'artere hepatique et d'autres agents augmentant l'oxygenation hepatique
WO2001035961A1 (fr) * 1999-10-29 2001-05-25 Nitromed, Inc. Methodes de traitement de maladies vasculaires caracterisees par une insuffisance du monoxyde d'azote

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016983A1 (fr) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Amelioration de la fonction vasculaire par modulation de la production ou de l'activite de l'oxyde nitrique endogene
WO1999038507A1 (fr) * 1998-01-30 1999-08-05 David George Le Couteur Inversion et prevention des aspects du vieillissement importants du point de vue clinique via l'administration par voie orale d'un vasodilatateur de l'artere hepatique et d'autres agents augmentant l'oxygenation hepatique
WO2001035961A1 (fr) * 1999-10-29 2001-05-25 Nitromed, Inc. Methodes de traitement de maladies vasculaires caracterisees par une insuffisance du monoxyde d'azote

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H.H. TING E.A.: "Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia", CIRCULATION, vol. 95, no. 12, 1997, pages 2617 - 2622, XP008003101 *
P.J. LAD E.A.: "Activation of rat lung soluble guanylate cyclase by sodium nitroprusside: effects of hemoglobin and reducing agents", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 103, no. 2, 1981, pages 629 - 637, XP008003108 *
S. DIKLOV: "Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals: effect of vitamin C", FREE RADICAL BIOLOGY & MEDICINE, vol. 27, no. 1-2, 1999, pages 170 - 176, XP001076816 *
S. TADDEI E.A.: "Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes", CIRCULATION, vol. 101, no. 25, 2000, pages 2896 - 2901, XP001076818 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite
US7566714B2 (en) 2003-11-17 2009-07-28 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Also Published As

Publication number Publication date
AU8852301A (en) 2002-03-13
WO2002017898A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2002017898A3 (fr) Compositions et procedes visant a induire une vasorelaxation
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
WO2005049000A3 (fr) Methodes et compositions pour le traitement des troubles du metabolisme
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
WO2002090332A3 (fr) Nouveaux derives d'aryl heteroalkyl amines
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
WO2004072031A8 (fr) Composes d'amides substitues tri(cyclo)
CA2416492A1 (fr) Traitement de la glycogenose de type ii
TW200626601A (en) Novel compounds
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
NO994900L (no) Forbindelser
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
WO2001091774A3 (fr) Traitement des ulceres chroniques
WO2001081332A3 (fr) Composes de 2-fluorobenzenesulfonyle utilises pour le traitement d'inflammations
WO2001070737A3 (fr) Composes therapeutiques permettant de traiter l'asthme et l'allergie et leurs methodes d'utilisation
WO2004028548A3 (fr) Agents neuroprotecteurs
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques
SE9803773D0 (sv) Compounds
SE0004101D0 (sv) New use
WO2001041755A3 (fr) Compositions et methodes pour le traitement local de maladies inflammatoires
DE60103034D1 (de) Neue phenylheteroalkylamin-derivate
SE0102641D0 (sv) Novel compounds
SE0000303D0 (sv) Novel compounds
WO2004026097A3 (fr) Traitement de steatose par hyperthermie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP